EMV conversion is coming to the United States and, much like in the aftermath of a disease outbreak, both fraudsters and fraud management teams will have to adapt and evolve to survive. Card fraud management to date charts a similar course to the case detection and treatment approach once taken to control the pneumonia bacteria. By the mid-1990s, the development of a pneumonia vaccine meant a drop in disease prevalence. Now the post-EMV landscape may well be the watershed, “vaccine,” moment for card fraud management. Fraud management teams must make vaccine development their first line of defense against fraud. Fraud management must also account for the evolution of fraud to ensure that vaccine development keeps up.